NeuroMab™ Anti-SPP1 Antibody,Clone NR3367P

Figure 1 shows the effect of MOR-6993 on tumor weight in a preclinical model of breast cancer.

Data are shown as mean ± SE of 8 animals, 7 animals, and 5 animals in the control, 25 mg/kg, and 50 mg/kg groups, respectively. *p<0.05, **p<0.01: Significantly different from the control group according to Dunnet's multiple comparison test.

Figure 2 shows the effect of MOR-6993 on metastasis in a preclinical model of breast cancer.

Data are shown as mean ± SE of 8 animals, 7 animals, and 5 animals in the control, 25 mg/kg, and 50 mg/kg groups, respectively. *p<0.05, **p<0.01: Significantly different from the control group according to Dunnet's multiple comparison test.

Figure 3 shows the neutralization of mouse osteopontin by MOR-6990 and MOR-6993.

Data are shown as mean ± SE of 8 animals, 7 animals, and 5 animals in the control, 25 mg/kg, and 50 mg/kg groups, respectively. *p<0.05, **p<0.01: Significantly different from the control group according to Dunnet's multiple comparison test.

Figure 4 shows the neutralization of human osteopontin by MOR-6990 and MOR-6993.

Data are shown as mean ± SE of 8 animals, 7 animals, and 5 animals in the control, 25 mg/kg, and 50 mg/kg groups, respectively. *p<0.05, **p<0.01: Significantly different from the control group according to Dunnet's multiple comparison test.